Andreas Jurgeit is to join Lundbeckfonden Emerge, the early stage investment unit of the Lundbeck Foundation, as a partner on 1 January 2019.
Andreas has been active in various operational and financing roles over the last decade. He was first exposed to biotech as a scientist collaborating with 3V Biosciences during his PhD and later joined Zurich-based venture investor Redalpine as Investment Manager. Most recently, as Director of the Merck Ventures Life Science team, he has conducted investments globally, with portfolio companies and board mandates in Europe, the US and Israel.
Andreas is 37 years old and is originally from Austria. He holds degrees in Molecular Biology from the University of Innsbruck and a PhD in Virology from the University of Zurich.